GlassScriptPhysician profile
Karen Griffith
NPI 1659372365
$844.10
in general payments reported to CMS, 2019-2025
9 companies · $540 in 2025
The $540 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.97 · 2020: $31.78 · 2022: $46.43 · 2023: $71.61 · 2024: $97.81 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $189.58 | 2022-2025 | Precision7, Total30 |
| Tarsus Pharmaceuticals, INC. | $169.08 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $150.01 | 2025 | Photrexa Viscous and Photrexa |
| Biotissue Holdings INC. | $96.84 | 2019-2022 | |
| Rxsight INC | $75.53 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Lkc Technologies, INC. | $71.38 | 2024-2025 | |
| Coopervision INC. | $56.56 | 2024 | Synergeyes Contact Lens |
| Alcon Research LLC | $19.19 | 2019 | |
| Bausch & Lomb Americas INC. | $15.93 | 2025 | Xiidra, Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.